Ucenprubart is an agonistic antibody to CD200R with the potential to treat inflammatory skin disease: preclinical development and a phase 1 clinical study

Abstract CD200R is a checkpoint inhibitory receptor central to the pathogenesis of inflammatory skin disease. Here we describe the development and phase 1 clinical study (NCT03750643) of ucenprubart, a CD200R agonist antibody to downregulate immune system inflammation. Preclinical studies find ucenp...

Full description

Bibliographic Details

Published in:	Nature Communications
Main Authors:	Anja Koester, Derrick R. Witcher, Mark Lee, Stephen J. Demarest, Scott Potter, Katie Werle, Scott Bauer, Diana Ruiz, Laurent Malherbe, Josh Poorbaugh, Andrew Glasebrook, Christoph Preuss, Gourab Datta, Ziqiao Wang, Jack Knorr, David Manner, Dipak Patel, Carsten Schmitz, Paul Klekotka, Ajay Nirula
Format:	Article
Language:	English
Published:	Nature Portfolio 2025-05-01
Online Access:	https://doi.org/10.1038/s41467-025-59147-w